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The safety of monoclonal antibodies in asthma
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bImmunoallergology Unit, AOU Careggi , University of
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ABSTRACT
Introduction: In the last two decades the knowledge of the mechanisms of the inflammatory processes
underlying asthma rapidly evolved, several key mediators (cytokines and receptors) were identified, and
10 the laboratory techniques have allowed us to synthesize monoclonal antibodies highly specific for
those target molecules. Nowadays, many biological agents are investigated in asthma (with anti IgE
being the only commercially available). The clinical efficacy of some biologics was demonstrated in
many cases, however, the safety issue has progressively emerged and has been recognized as a crucial
aspect.
15 Areas covered: We summarized the currently available knowledge on the safety and side effects of
biologics in asthma, as derived by reviews, meta analyses and clinical trials. PubMed was searched with
the terms anti IL-x [AND] safety [OR] side effects, within the categories “clinical trial”, meta-analysis” and
“review”. Case reports were excluded. The authors collegially selected the relevant entries to be
included.
20 Expert opinion: Overall, the safety of most of the investigated agents seems to be satisfactory, a certain
risk of side effects remains present, and is variable for the different molecules. Thus caution must be
paid in evaluating the risk to benefit ratio. Specific biomarkers to predict the response to each
biological are urgently needed to improve the safety profile.
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25 Asthma, which remains a high-prevalence disease worldwide,
[1,2] is currently recognized as a ‘heterogeneous disease’,[3]
and this definition profoundly differs from what stated only
few years ago in Guidelines, when asthma was considered as a
single and uniform disease. This is the result of the more
30 detailed knowledge that we have gained on clinical presenta-
tion, biological/immunological aspects, functional  behavior,
and treatment approaches. Consequently, there have been
many attempts to identify distinct phenotypes of asthma,
according to clinical and biological criteria.[4] So far, a quite
35 clear distinction can be made only between the T-helper 2
(TH2) and low-TH2 phenotypes.[5] Within these large and
partially overlapping groups, allergic asthma (AA) remains
the paradigm of TH2-driven asthma, whereas other forms,
such as adult-onset or smoke-related or  obesity-related
40 asthma, well represent some of the usual low-TH2
presentations.
Starting from the well-known IgE-mediated mechanisms
underlying allergic asthma, the pathophysiology of the disease
was progressively and rapidly elucidated in the past two dec-
45 ades, and also applied to other forms of asthma. Cytokines,
receptors, cell function, and chemokines were progressively
identified and dissected. The evolving knowledge, in addition
to the evolving biotechnology, allowed to identify precise
molecular targets to be addressed by specifically constructed
50molecules to be applied in asthma, especially in the more
severe forms.[6,7] This is the era of ‘precision medicine’,[8,9]
where each single molecular target can be inhibited by biolo-
gical agents (BA), monoclonal antibodies (MAbs) in particular.
In less than 15 years, many MAbs targeted to single compo-
55nents of the immune-mediated inflammation of asthma were
synthesized, tested, and proposed for clinical use.[10] In par-
allel to clinical use and large-population trials, the problem of
the safety and tolerability of these approaches rapidly
emerged: as any other drug, MAbs are not totally devoid of
60side effects.[11,12]
The clinical efficacy, in the view of the personalized med-
icine, remains the primary goal of MAb-based therapy but,
due to the costs and affordability problems, the safety
assumes a comparable importance. Here, we reviewed  the
65available data on the tolerability and safety profile of the
MAbs currently used or under evaluation for the treatment
of asthma (listed in Table 1). We searched PubMed for each
of them using the terms name of the molecule [AND] safety
[OR] side effects AQ4, within the categories ‘clinical trial ’, ‘meta-
70analysis’ and ‘review ’. Case reports were excluded. The
authors collegially selected the relevant entries to be
included and discussed.
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2. An overview on the pathogenic mechanisms of
asthmaAQ5  
75 During the past two decades, a great research effort has been
undertaken to clarify the complex mechanisms, which regulate
airways inflammation in asthmatic patients (Figure 1). The vast
majority of our knowledge about the immunological aspects of
asthma derives, for historical reasons, from the allergic model.
80 In such case, the triggering mechanism that starts the inflam-
matory processes is well known: the specific IgE–allergen–mast
cell interaction. It has become quite clear that the reaction of
inhaled allergens with IgE-specific antibodies bound to FcεRI
receptors on the surface of mast cells is not sufficient to
85 account for the persistent histological, pathophysiological, and
clinical alterations that characterize the allergic asthma. The
definition of phenotypic and functional activities of different T
cell subsets based on their profiles of cytokine secretion has
been of the primary importance. One type of T helper cells
90(TH1) produces interleukin (IL)-2 and IFN-g, whereas the other
type (TH2) secretes IL-4, IL-5, IL-9 , IL-13, and IL-10, but not IL-2
and IFN-g.[13,14] In particular, atopic subjects have a pre-exis-
tent background that interacts with external factors (allergen
exposure, maternal factors, infections, intestinal microbiota),
95leading to an overproduction of IgE specific for ubiquitous
and innocuous antigens. This abnormal production of IgE is
the consequence of a relative imbalance between TH1 and
TH2T cells. In fact, IL-4 and IL-13 favor IgE synthesis, whereas
IL-5 increases eosinophil activation and survival.[15] IL-13, is
100actively involved in inducing goblet cell metaplasia and bron-
chial hyper-reactivity, and prime the upregulation of the adhe-
sion molecule VCAM-1 and ICAM-1 on endothelial cells, that is a
key step for eosinophils migration.[16] However, it should be
remembered that T cells may play an important role also in
105non-atopic asthma. In fact, similarly to what observed in atopic
asthmatics, the biopsies taken from intrinsic asthmatics are
characterized by large numbers of eosinophils and activated T
lymphocytes.[17] Non-allergic asthmatics also display increased
levels of IL-2 and IL-5, but not IL-4.[18]
Article highlights
● Asthma is a heterogeneous disease. Despite the clinical and func-
tional aspects are common, different phenotypes/endotypes can be
recognized. Allergic asthma is the most studied model.
● Several cytokines, cells and receptors are currently recognized as
pivotal elements in asthma-related inflammation (IgE, IL-4, IL-5,
IL13, IL-17)
● Monoclonal antibodies specific to relevant targets of inflammations
are now available, and many of them are undergoing clinical trials.
● For anti IgE (in use since >10 years), there is a large amount of
evidence. Efficacy and safety data are available for many of the
biological agents from the published clinical trials.
● Biologicals (in particular Monoclonal Antibodies) may exert both
favourable and undesired side effects with various mechanisms.
● Non-specific adverse events (headache, local reactions, diarrhea etc.)
invariably resulted to be more frequent in active than in placebo
groups.
● Overall, the biological agents tested in asthma displayed an overall
efficacy to safety favourable profile, but this is not applicable at the
same extent to each single agent.
● A ‘precision medicine’ approach, including the search for biomarkers,
would be necessary to appropriately prescribe biological agents,
maintaining an optimal safety profile.
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Figure 1. Schematic view of the allergic reaction. APC-DC: antigen presenting
cell-dendritic cell; Eos: eosinophil: MAST: mastcell; Neu: neutrophil; TSLP: thymic
stromal lymphopoietin.




Omalizumab  Anti-IgE Humanized Commercialized (Xolair ™)
Ligelizumab Anti-IgE Humanized  IIb
Benralizumab Anti-interleukin (IL)-5 receptor Humanized  II
Mepolizumab Anti-IL-5 Humanized  III European Medicines Agency and US Food and Drug
Administration (FDA) approved (Nucala™)
Reslizumab Anti-Il-5 Humanized  III FDA approved
Pascolizumab Anti-Il-4 Humanized II
Annukizumab Anti-Il-13 Humanized II
Lebrikizumab Anti-IL-13 Humanized  III
Pitrakinra Anti-IL-4/IL-13 receptor Humanized  IIb
Tralokinumab Anti-IL-13 Human  IIb
Pitrakinra IL-4/IL-13 antagonist Mutein  IIb (withdrawn)
Dupilumab  Anti-IL-4/IL-13 Human  IIb
Infliximab  Anti-tumor necrosis factor-α (TNF-α) Chimeric III (withdrawn)
Golimumab  Anti-TNF-α Human III (withdrawn)
Etanercept Soluble TNF-α receptor Fusion protein III (withdrawn)
Brodalumab  Anti-IL-17 Human II
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110 Eosinophils represent 1–6% of the circulating white blood
cells. They are important effectors of the allergic inflammatory
response, playing a primary role in the pathogenesis and
severity of chronic inflammatory disorders of the airways.[19]
The accumulation in the target tissues and the activation of
115 allergen-specific TH2-like cells as well as mast cells through an
IgE-dependent pathway play a central role in orchestrating the
airway allergic inflammation, by the recruitment of effector
cells, mainly eosinophils. In this regard, different cytokines,
such as IL-3, IL-5, and GM-CSFAQ6 are involved. IL-5 appears to
120 be the most specific for eosinophils by promoting their differ-
entiation from bone marrow precursors, enhancing their adhe-
sion to endothelial cells, prolonging their survival in target
tissues and priming them for many activities as effector cells.
[20–22] The recruitment of eosinophils to airways wall is regu-
125 lated by the production of chemokines, such as eotaxins 1, 2,
and 3 now called CCL11, CCL24, and CCL26, respectively.[23]
In non-atopic ‘intrinsic’ asthma, the accumulation and acti-
vation of T cells able to produce cytokines, particularly IL-5,
may be responsible for the peculiar eosinophilic airway inflam-
130 mation. Eosinophils can damage the respiratory mucosa by
releasing basic proteins, oxygen-free radicals, and lipid med-
iators, such as leukotriene C4 and  platelet-activating factor,
contributing to microvascular leakage, bronchoconstriction,
mucus secretion, and shedding of the airway epithelium.
135 Eosinophils has been demonstrated to be also able to elabo-
rate cytokines, such as IL-3, TGF-β, GM-CSF, IL-1, IL-6, and IL-5.
[24] Recently, a key role in eosinophilic asthma has been
attributed to the so called ‘type 2’ innate lymphoid cells
(ILC2 cells), able to produce IL-5 as well as IL-9 and IL-13.[25]
140 ILC2 cells lack antigen-specific receptors, but like TH2 cells,
they react to the epithelium-derived cytokines IL-25, IL-33, and
thymic stromal lymphopoietin (TSLP).[26]
3. Pathogenic mechanisms of adverse reaction to
biological agents
145 The safety of BA is an important field of research consider-
ing their growing clinical applications. Adverse events (AEs)
should be defined as any untoward medical occurrence
associated with the use of a drug, whether or not consid-
ered drug related (Table 2). The safety profile of biologicals
150 is negatively impacted by their immunogenicity, which
leads to the production of specific anti-drug antibodies
(ADA).[27]  Similar to other biologicals, therapeutic MAbs
are structurally immunogenic. They are classified as chimeric
(variable regions from murine sources and constant regions
155 from human immunoglobulins) or humanized (containing
only the complementarity-determining regions of a murine
immunoglobulin with the remaining being human), and
fully human (Figure 2). These latter usually elicit minor,
subclinical, and transient phenomena, but, sometimes, they
160can induce complete cellular and humoral immune
responses, which impact the efficacy. Various types of ADA
were observed during biological treatments, mostly IgG, but
also IgE, IgM, and IgA.[28] Patients developing high levels of
ADA are more likely to show acute hypersensitivity reac-
165tions, and both IgE and non IgE-mediated mechanisms may
be involved. Other adverse events, such as serum sickness-
like reactions appear to be associated with the presence of
ADA, related to the formation of complement-binding
immune complexes, with subsequent immune complexes
170deposition, complement activation, and inflammatory infil-
tration around small vessels. In fact, at immunofluorescence,
the presence of complement deposition around vessels of
skin specimens can be observed.[29] In addition, data from
clinical trials and from real-life clinical practice suggested
175that the currently used biologicals may constitute a risk
factor for the reactivation of latent bacterial infections or
parasitic infestations as in the case of tumor necrosis factor-
α (TNF-α) blockers. In general, TH1 cells are more suitable
for protection against intracellular infection agents, such as
180Mycobacterium tuberculosis whereas the optimal reaction
against parasites is provided by TH2 cells and IgE antibodies
and eosinophils. Among biological agents used for the
treatment of severe asthma and their association with the
risk of infections, anti-IL-5 MAbs have been closely followed-
185up. The role of T cells in the protection of mycobacterium is
indirectly demonstrated by the effects of TNF-α blockers,
also proposed for the treatment of severe forms of asthma.
These biological agents are able to interfere with the
 mycobacterium- specific-induced proliferation and cytokine
190production by T cells, thus increasing the risk of infection
or reactivation. TH1 cells produce IFN-γ, IL-2, and TNF-β,
which activate the macrophages responsible for cell-
mediated immunity to intracellular pathogens.[30]
Table 2. Adverse reactions to biological agents.
Target-related events
●  Infections
●  Increased tumor susceptibility
●  Autoimmunity (ADA, with possibly reduced efficacy of the MAb)
 Drug-related events
●  Infusion reactions
●  Local (immediate or delayed)








Monoclonal antibodies: structure and immunogenicity
Figure 2. Schematic representation of therapeutic monoclonal antibodies and
their structure-related immunogenic profile. ADA: anti-drugantibodies.
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4.  Anti-IgE (omalizumab)
195 For historical reasons, IgE was immediately regarded as an opti-
mal target for a MAb-based strategy. In fact, IgEs are the primary
trigger of the allergic reaction. The atopic subject produces
abnormal amounts of allergen-specific IgE, which bind the high
affinity receptor (FCεRI), widely distributed on tissue mast cells
200 and circulating basophils. The rationale of the anti-IgE strategy
was to synthesize a MAb capable of specifically bind the heavy
chain of the circulating IgE, thus preventing them from engaging
with the receptor. The MAb obtained was a humanized one
(human IgG with a 5% murine fraction), named omalizumab.
205 [31] Omalizumab underwent numerous phase II and phase III
clinical trials in the past 15 years,[32] and was then approved for
commercial use more than 10 years ago. Its indication is severely
uncontrolled asthma due to perennial allergens with a total IgE
concentration of 30–1 500 kU/L and a body weight between 50
210 and 120 kg. Due to the long-standing clinical use, there is now a
large amount of data available on its efficacy [33–35] and safety.
Looking at the clinical trials so far published, the occurrence of
AEs, including severe (SAEs) ones, was negligible and approxi-
mated that of placebo groups.[36,37] In particular, in the pub-
215 lished trials the most frequently reported AEs were local
(induration/irritation at the injection site) or systemic (headache,
pharingytis, or rhinitis), none of them exceeding 10% of patients.
Since the beginning, one of the major concerns was the risk
of inducing or unmasking malignancies, since MAbs interferes
220 with the immune system. After many years of clinical use, it
can be stated that the incidence of malignancies in the oma-
lizumab-treated patients does not differ from that expected in
the general population.[38,39] Another possible safety pro-
blem is the occurrence of parasitosis, since IgE are well
225 known to be actively involved in the natural defensive
response to parasites. According to the currently available
data, an increased occurrence of parasite infestation during
omalizumab treatment was not observed,[40] although a
slight but not significant excess in geoelminthic infestations
230 (in at risk regions) was reported in a single study.[41] Finally,
some cases of anaphylaxis, anaphylaxis-like reactions or serum
sickness following omalizumab treatment have been sporadi-
cally reported.[42,43] In some case reports, cases of omalizu-
mab-related AEs on the pathogenic mechanism  were
235 sustained by IgE antibodiesAQ7 directed against additives that
are present in the drug formulation.[44] Indeed, according to
the more recent survey conducted in the United States, the
incidence of anaphylaxis or anaphylaxis-like events was about
0.09%, with 16 out of the 77 reported events occurring more
240 than 2 h after the administration, thus leaving the diagnosis of
anaphylaxis uncertain.[45] Based on these results, in the
 United States, an observation period of at least 2 h and the
prescription of autonjectable epinephrine are recommended,
whereas those recommendations are not applied in most
245 other countries. When omalizumab was first commercialized
and introduced in clinical practice, some reports of Churg–
Strauss disease possibly related to the drug were published.
These cases were attributed to the systemic steroid withdra-
wal that unmasked a pre-existing disease. Nowadays, the
250 Churg–Strauss syndrome is suggested as a promising,
although off-label, indication for omalizumab.[46]
In conclusion, looking back to more than 15 years of clinical
trials and clinical use in real life, the safety profile of omalizu-
mab is extremely satisfactory. Mild AEs (e.g. local) may occur,
255but systemic and/or SAEs are very rare, if not anecdotal. From
a very conservative and cautious point of view, a 2-h period of
observation after each injection (and the prescription of auto-
injectable epinephrine) are applied in the United States, but
not in the remaining countries.
2605. Anti-IL-5 and IL-5Ra chain (mepolizumab,
reslizumab, benralizumab)
IL-5 is secreted mainly by Th2 cells, mast cells, natural killer T
cells, basophils, eosinophils, and type-2 ILCs. The IL-5R is a
heterodimer composed of β-subunit, responsible for binding
265of IL-5 and expressed both on progenitors of mature eosino-
phils but also by basophils, and the alpha subunit, necessary
for signaling. IL-5 induces the maturation, activation, and
recruitment of eosinophils.[47] The BA interfering with IL-5
and its receptor proposed for asthma are mepolizumab and
270reslizumab (anti-IL-5 MAbs) and benralizumab (anti-IL-5Ra
MAb).[24] Differently from the two anti-IL-5 MAbs, benralizu-
mab targets IL-5Ra chain receptor and might thus also affect
leukocytes via antibody-dependent cell-mediated cytotoxi-
city.[48]
275To date, few clinical trials with benralizumab have been
completed, showing a significant efficacy in patients with mild-
 to-severe asthma along with a reduction in peripheral blood
and sputum eosinophils and eosinophil cationic protein. A
single dose administered intravenously and subcutaneous
280multiple dose of benralizumab reduced eosinophil counts in
airway mucosa and submucosa  in sputum, and suppressed
eosinophil counts in bone marrow and peripheral blood.[49–
51] Only nonspecific mild AEs (headache, fatigue) were
described, and local reactions occurred in about 5% receiving
285subcutaneous injections.
More data are available for mepolizumab, that invariably
showed a significant benefit in eosinophilic asthma, character-
ized by the decrease in the frequency of exacerbations,
increase in FEV1 AQ8, improvement in quality of life, along with a
290significant decrease in blood and sputum eosinophilia.[52–56]
This was confirmed in a recent meta-analysis.[57] The most
commonly reported AEs were nasopharyngitis, headache,
chest pain, facial flushing, fatigue, upper respiratory tract
infection in 10 –25% of actively treated patients on average,
295with few SAEs not related to treatment. Mepolizumab was
usually given intravenously. In the case of subcutaneous
administration, local side effects (induration, pain) occurred
in about 10% patients (one case of anaphylaxis reported).
Similar results were obtained with reslizumab in asthmatic
300patients with sputum eosinophil levels of 3% and more.
[58,59] In this case, there was not a significant difference in
common AEs between placebo and active groups, but  two
cases of anaphylaxis were reported with intravenous
reslizumab.
305As with anti-IgE, a possible safety problem is the occur-
rence of parasitic infestation, since eosinophils are involved in
the natural defense against parasites. Indeed, experiments in
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parasite-infested mice and receiving anti IL-5 antibodies
showed no change in immune response,[60] but no data are
310 available in humans. An indirect evidence of the safety of IL-5/
IL-5Ra blockers is that patients lacking eosinophils, do not
display any abnormality related to eosinophil reduction.[61]
Concerning the risk of malignancies, it is important to note the
role of eosinophils in both anti-carcinogenic and pro-carcino-
315 genic effects depend on many factors mainly on the type of
cancer. Eosinophil infiltration is considered unfavorable in
Hodgkin’s lymphoma, but conversely, it was associated to a
favorable prognosis in solid cancers (e.g. colorectal or pro-
static). A variety of cytokines and factors produced by eosino-
320 phils such as major basic protein, eosinophil cationic protein,
eosinophil-derived neurotoxin have either anti-tumor effects
or stimulate tumor progression.[62] Although clinical experi-
ence of IL-5 blockers in asthmatic patients is limited to clinical
trials, additional information of the safety profile of these BA
325 were obtained by the data of patients with the hypereosino-
philic syndromes treated with mepolizumab for several years:
these subjects did develop no AE at all.[63]
6. Anti IL-4 and IL-13
Dupilumab antagonizes the effects of both IL-4 and IL-3 by
330 blocking the IL-4 receptor alpha chain. Wenzel and colleagues
described the safety results in a clinical trial involving 104
asthm atics treated with dupilumab or placebo.[64] In this
study, the overall proportion of AE in the two groups was
similar (77% vs. 81%). The reported AEs were mild or moderate
335 and only four patients had serious adverse event ( three in the
placebo group and one in the dupilumab group). There was
no fatal event and most AEs were judged by investigators as
not related to study drug. Six patients discontinued therapy:
three in the placebo group (psoriasis, asthma exacerbation,
340 and upper respiratory tract infection) and three in the dupilu-
mab group (worsening of bipolar disorder, angioedema and
increase in asthma symptoms). The most common adverse
events were injection-site reactions (29%), nausea, headache,
and naso pharingitis (8–13%), which occurred more frequently
345 with dupilumab. One case of angioedema, judged as treat-
ment-related was reported. In addition, in 4/52 patients an
unexpected increase in eosinophil count, not associated with
asthma worsening was described.
The safety of pitrakinra, a mutein antagonizing both IL-4
350 and IL-13, was described by Wenzel and colleagues in a clinical
trial in asthmatic people. Two group of patients, the first
treated with pitrakinra by subcutaneous injections and the
second one by inhalation route, were investigated in the
same trial. The most frequent symptoms recorded were
355 about general disorders (headache, fatigue, musculoskeletal
pain) and injection site reactions. Other reported adverse
events were related to the nervous system (somnolence, dizzi-
ness), respiratory, and thoracic disorders (wheezing, chest dis-
comfort, dyspnea, and nasal obstruction) and gastro-enteric
360 symptoms (nausea, abdominal discomfort, and diarrhea). All
those AEs were mild and occurred in about 10% of patients.
[65] Despite the initial enthusiasm, no further trial with pitra-
kinra was conducted after 2007.
The use of human anti IL-13 MAb lebrikizumab in asthma
365was explored in few studies, with conflicting results. A pooled
analysis of two phase II trials reported a significant reduction
in asthma exacerbations, with a marginal effect on pulmonary
function.[65] Corren et al. [66 ,67] showed a significant clinical
efficacy of the treatment only in a subgroup of patients with
370high blood periostin, whereas another trial failed to demon-
strate a clinical efficacy.[68] The first study involved 219 adult
patients with asthma. The overall occurrence of adverse
events was similar in the active and placebo group, with the
exception of musculoskeletal pain, more frequent in the active
375group (13% vs. 5%). In the second ranging phase II (dose
ranging) trial in mild asthma [68], the safety profile was
good as well, with a similar proportion of AEs in placebo and
active arms. Most of AEs were moderate, only one of the six
SAEs in the lebrikizumab arm (Lofgren syndrome) was consid-
380ered drug related. A third small study with lebrikizumab in 29
mild asthmatic patients, evidenced 61 AEs, with a greater
incidence in the placebo group. Only one event (decreased
platelet count) was judged as drug related. No patient was
withdrawn because of AEs.[69]
385Another anti IL-13 drug, tralokinumab, was evaluated in
194 asthmatic patients in a phase II study, at three different
dose 150, 300, or 600 mg. The six reported SAEs were equally
distributed between groups and not treatment related. The
most frequent AEs in the Tralokinumab arm were asthma,
390headache, nasopharyngitis, and local reactions. Interestingly,
urinary tract infections were reported in 4% of the active-
group patients as well as an increased eosinophil count in
2–6% of patients at week 13.[70]
7.  Anti-IL-17
395Busse and colleagues described results about a clinical trial of
 phase IIa with in asthmatic patients with the anti-IL-17 MAb
Brodalumab at different doses. The safety was evaluated mon-
itoring adverse events and laboratory parameters. The occur-
rence of AEs was similar for all dosages, and the most
400common events were described in upper and lower airways
(asthma, upper respiratory tract infection, nasopharyngitis,
oral candidiasis, and sinusitis), local injection site reaction,
and cutaneous events such as erythema. AEs were most fre-
quent in the brodalumab group than in placebo one, includ-
405ing events that led to discontinuation. During the trial, seven
patients showed serious adverse events, and two patients (one
active and one placebo) had an asymptomatic decrease of
neutrophil count.[71]
8. TNF-α antagonists
410Among the TH2-low or no primarily TH2-driven asthma some
phenotypes are well recognized including: adult onset and
obesity associated asthma and overlapping syndromes.[72–
74] In such cases, a neutrophilic or pauci-cellular, rather than
eosinophilic, inflammation seems to predominate. Based on
415these observations, a mainly TH1-driven inflammation strategy
was hypothesized. TNF-α is known as a central mediator of the
Th1 inflammation, involved in the pathogenesis of many
inflammatory diseases, such as Crohn disease, rheumatoid
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 arthritis, and various neuropathies.[75,76] In some forms of
420 asthma, TNF-α can enhance mucus production, smooth mus-
cle proliferation, and epithelial disruption. Thus, TNF-α antag-
onism was hypothesized to be an optimal therapeutic target.
There were some already in use agents (TNF-α soluble recep-
tor, etanercept, or TNF-α antagonists golimumab and inflixi-
425 mab) to be also tested in asthma. The earliest studies showed
some beneficial effect of etanercept and infliximab in refrac-
tory asthma where increased levels of TNF-α were well ascer-
tained.[77–79] Nonetheless, similar studies performed in COPD
evidenced an excess of SAEs, such as malignancies,[80] and a
430 randomized  double-blind placebo controlled trial in asthma
had to be interrupted due to the unacceptable rate of AEs.[81]
However, these data must be compared with those obtained
in anti-TNF- α-treated patients suffering from rheumatic dis-
eases in which there was no evidence for an increased risk
435 of lymphoma and solid cancers.[82–84] In addition, those
diagnosed with cancer during or after anti- TNF-α treatment
have not been shown to have a worse prognosis than anti-
TNF-α naive patients.[85] Noticeably, the frequency of local
(injection site) reactions with TNF-α antagonists is overall low
440 (5%).[86]
Although the TNF-α antagonism remains a reasonable
strategy in some forms of asthma, the available results in
this kind of patients display an  unfavorable  benefit- to-risk
rate, and this approach in asthma has been abandoned.
445 9. Conclusions
The knowledge on the pathogenic mechanisms of asthma has
rapidly evolved in the past two decades. Although a precise
phenotyping or endotyping cannot still be well defined, some
biological characteristics can be reasonably attributed to some
450 specific forms of asthma (e.g. TH-2 high or TH2-low). In this
context, biological drugs (namely monoclonal antibodies) spe-
cifically constructed to antagonize relevant mediators and
cytokines (e.g. IgE, IL-5, IL-4, IL-13) have been clinically tested.
According to the available results, many of these approaches
455 are clinically effective especially in the most severe forms of
asthma. In parallel, the safety aspects of biological drugs
became emergent. So far, the safety profile results favorable
for  anti-IgE and  anti-IL-5 monoclonal antibodies, which are
undergoing clinical trials and practical use since many years.
460The efficacy/safety ratio remains a matter of debate for the
new biologicals ( anti-IL-13, anti-IL-4, and anti-IL-17), which are
more recent in development (Table 3). Some other
approaches, that are justified from an immunological point
of view (TNF-α antagonism), produced an unacceptable rate
465of severe adverse events, and were abandoned at least in
asthma.
In the near future, the ‘personalized’ medical approach will
become more and more relevant,[87] with an appropriate
investigation of biomarkers. Nonetheless, it must be kept in
470mind that acting on immunological effectors is not totally
devoid of risk,[11] and that a careful and strict surveillance is
mandatory needed.
10. Expert opinion
Asthma is currently recognized as a heterogeneous disease,
475and different phenotypes/endotypes have been proposed in
the past decade. This fact is directly linked to the more and
more detailed knowledge on the mechanisms underlying the
inflammatory aspects (mainly derived from the allergic model).
In this framework, many sensible molecular targets have been
480identified,  which can be selectively blocked by monoclonal
antibodies (biological agents). An anti-IgE treatment is already
in clinical use since more than 10 years, whereas other biolo-
gical are under investigation in clinical trials, often with good
clinical results. The increasing number of patients treated,
485both in clinical practice and trials, attracted the medical atten-
tion on the safety aspect, especially for those drugs that are
expected to be commercialized soon.
Indeed, the field is of primary relevance, since all those
biological agents are used for severe/refractory/steroid-
490 dependent asthma, which represent a clinical challenge and
a socio economic burden, and where the side effects of sys-
temic steroids are a real occurrence. The results so far available
are encouraging in term of clinical efficacy, and the safety is
overall satisfactory. The majority of side effects reported are
495non specific (e.g. headache, flu-like symptoms, local reactions)
and mild, but treatment-emergent severe adverse events (e.g.
anaphylaxis with anti-IgE) can exceptionally occur. Some
events seem to be drug-specific (e.g. eosinophilia with dupi-
lumab or anti-IL-13), but difficult to interpret from a patho-
500genic viewpoint. So far, no clear risk factor for severe adverse
Table 3. Brief summary of the reported adverse events in clinical trials (percentage of patients are in parentheses).




induration at injection site (<10%)
Anaphylaxis-like reactions (~0.09%)
Churg–Strauss s yndrome (exceptional case reports)
Anti IL-5 (mepolizumab,
Nucala™)
Nasopharyngitis, headache, upper respiratory infection
(10–25% of patients. Injection site reaction (<10% of
patients)
Anti-mepolizumab Ab detection (5%)
 One case of anaphylaxis with s.c. administration
Anti IL-5 (reslizumab) Similar occurrence in placebo and active groups  Two cases of anaphylaxis (0.05%) with i.v. administration
Anti IL-4/IL-13 (dupilumab) Pharyngitis, headache (8–13%) Injection site reaction
(30%)
 One case of angioedema
4/52 (7%) hypereosinophilia in the active group
Anti IL-13 (lebrikizumab) Injection site reactions (~10%)
Similar rate of AEs in active and placebo groups, mostly
mild
 One case of Lofgren syndrome and 1 case of low platelet count
probably treatment related
Anti IL-13 (tralokinumab) Asthma, headache, and nasopharyngitis more frequent in
active group (6–13%)
Urinary tract infection (4%)
Increased eosinophils (2–6%)
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events could be identified in clinical trials, but this should
induce caution in view of the commercialization, since some
events are quite rare and their pathogenesis can be identified
only in the post-marketing phase, as happened for alpha-gal
505 and cetuximab.[88] Based on the previous experience with
anti-IgE, it is opinion of the authors that a precautional period
of observation (at least 30 min after administration) should be
recommended for the newly marketed treatments. Another
weak aspect of MAb-based treatment in asthma is that the
510 effects of most cytokines are extensively overlapping, so that
the blockage of a single molecule may be insufficient to
achieve a meaningful effect.
Within this context, it is clear that the investigation on the
role of MAbs in asthma therapy remains of primary relevance 
515 due to the fact that it covers those forms of asthma where
standard therapy is not sufficient. On the other hand, this
approach will not be fully effective until specific biomarkers
to identify the subjects suitable for a given treatment and who
will respond to that treatment are defined. Currently, very few
520 biomarkers with respect to the number of possible targets and
drugs are indeed available (e.g. IgE, bronchial/circulating eosi-
nophils, and periostin). This is the optimal goal of which is
called ‘precision’ or ‘personalized’ medicine.
The field of research with MAbs for ‘difficult asthma’ will
525 certainly remain alive and progressing in the near future, also
because the basic research on the mechanisms will be further
refined. In addition, it is expected that the development of
technology will lead to a sensible reduction in the costs of
biological, that remains a main drawback . In the very near
530 future, several  anti-IL-5 compounds will be commercialized 
based on the good results obtained in clinical trials. This
biological represents a special case, since IL-5 is specifically
committed to eosinophils and has relatively few actions over-
lapping with other cytokines. In fact, clinical results are rele-
535 vant in those patients with high eosinophil count (that
represent in turn the biomarker). Another expected entry in
our armamentarium would be dupilumab, since it antagonizes
both IL-4 and IL-13 at the same time, and thus can partially
overcome the overlapping effects of the two cytokines. The
540 commercial use of anti-IL-4 or IL-13 alone, anti-IL-17 seems to
be a more distant perspective.
It is clear that when a new drug is released for clinical use,
the post-marketing data on the safety start to rapidly accu-
mulate, and this is expected to be advantageous to identify
545 the possible risk factor and to better define the safety to
efficacy ratio.
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